Table 1 Distribution of the study population among areas and age groups, and seroprevalence (Positivity rate) of the serologic markers of transfusion-transmitted infections (TTIs)
Variable | Blood donors: N (%) | Prevalence: N (%) | |||||
|---|---|---|---|---|---|---|---|
Anti-HIV1/2 | HBVsAg | Anti-HCV | Anti-T. palladium | MI | Total of TTIs | ||
Overall | 10897 | 285 (2.61) | 607 (5.57) | 153 (1.40) | 624 (5.72) | 65 (0.59) | 1734 (15.91) |
Age | |||||||
18–27 years | 3950 (26.25) | 32 (0.81) | 157 (3.97) | 42 (1.06) | 197 (4.98) | 25 (0.63) | 453 (11.46) |
28–37 years | 4183 (38.39) | 225 (5.37) | 356 (8.51) | 103 (2.46) | 355 (8.48) | 21 (0.50) | 1060 (25.34) |
38–47 years | 2764 (25.36) | 28 (1.01) | 94 (3.40) | 8 (0.28) | 72 (2.60) | 19 (0.68) | 221 (7.99) |
P value | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | 0.576 | < 0.001 |
Residence | |||||||
Al Douiem | 3331 (30.60) | 47 (1.41) | 179 (5.37) | 62 (1.86) | 169 (5.07) | 12 (0.36) | 469 (14.07) |
Kosti | 4152 (38.10) | 164 (3.94) | 211 (5.08) | 28 (0.67) | 215 (5.17) | 27 (0.65) | 645 (15.53) |
Rabak | 3414 (31.30) | 74 (2.16) | 217 (6.35) | 63 (1.84) | 240 (7.02) | 26 (0.76) | 620 (18.16) |
P value | < 0.001 | < 0.001 | 0.047 | < 0.001 | < 0.001 | 0.086 | < 0.001 |